Loviride

Loviride is an experimental antiviral drug manufactured by Janssen (now part of Janssen-Cilag) that is active against HIV. Loviride is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that entered phase III clinical trials in the late 1990s, but failed to gain marketing approval because of poor potency.^[1] It is of clinical significance only in those patients who were enrolled in clinical trials to evaluate loviride (e.g., CAESAR^[2] and AVANTI^[3]), because in those trials loviride was often given alone and with no companion drug, leading to a high probability of developing reverse transcriptase mutations such as K103N which result in cross-class resistance to the NNRTIs efavirenz and nevirapine.

Loviride

Clinical data
Other names	R089439; loveride[citation needed]
ATC code	None
Identifiers
IUPAC name 2-[(2-Acetyl-5-methylphenyl)amino]-2-(2,6-dichlorophenyl)acetamide
CAS Number	147362-57-0 N
PubChem CID	3963
ChemSpider	3826 Y
UNII	3S1R1LZ09H
KEGG	D04786 Y
ChEMBL	ChEMBL37624 Y
CompTox Dashboard (EPA)	DTXSID60869958
Chemical and physical data
Formula	C17H16Cl2N2O2
Molar mass	351.23 g·mol−1
3D model (JSmol)	Interactive image
SMILES Clc1cccc(Cl)c1C(Nc2cc(ccc2C(=O)C)C)C(=O)N
InChI InChI=1S/C17H16Cl2N2O2/c1-9-6-7-11(10(2)22)14(8-9)21-16(17(20)23)15-12(18)4-3-5-13(15)19/h3-8,16,21H,1-2H3,(H2,20,23) Y Key:CJPLEFFCVDQQFZ-UHFFFAOYSA-N Y
NY (what is this?)  (verify)